Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Forat Lutfi, MD, Ankit Kansagra, MD, Moaath Mustafa Ali, MD, Ali Bukhari, MD, Jonathan Siglin, BS, Jingsheng Yan, PhD, Santanu Samanta, MD, Noa G. Holtzman, MD, David Gottlieb, MD, Dong Won Kim, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Jean A. Yared, MD, Nancy M. Hardy, MD, Jason Molitoris, MD, Pranshu Mohindra, MD, Aaron P. Rapoport, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141231

Published: 2020

Journal Articles

Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas

Ajay Major, MDMBA, Justin Kline, MD, Theodore G. Karrison, PhD, Paul A S Fishkin, MD, Amy S Kimball, MD PhD, Adam M Petrich, MD, Sreenivasa Nattam, MD, Bethany G Sleckman, MD, Kenneth Cohen, MD, Koen van Besien, MD PhD, Aaron P. Rapoport, MD, Sonali M. Smith, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-134750

Published: 2020

Journal Articles

Pseudo-Allogeneic CAR-T Therapy after Allogeneic Stem Cell Transplantation in Relapsed/Refractory B-Cell NHL

Jonathan Siglin, BS, Forat Lutfi, MD, Ali Bukhari, MD, Noa G. Holtzman, MD, Dong Won Kim, MD, Moaath Mustafa Ali, MD MPH, Aaron P. Rapoport, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-136187

Published: 2020

Journal Articles

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dong Won Kim, MD, Forat Lutfi, MD, Facundo Zafforoni, BS, Moaath Mustafa Ali, MD MPH, Ali Bukhari, MD, David Gottlieb, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Nancy M. Hardy, MD, Jean A. Yared, MD, Aaron P. Rapoport, MD, Jennie Y. Law, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141992

Published: 2020

Journal Articles

Detailed Immunophenotypic Profiling of Peripheral Blood Immune Cells in Patients with Hematologic Malignancies after Sars-Cov-2 Infection

Forat Lutfi, MD, Jonathan Siglin, BS, Gabriela Sanchez-Petitto, MD, Ali Bukhari, MD, David Gottlieb, MD, Dong Won Kim, MD, Brandon Cooper, Michelle Fleyshman, MD, Diego De Miguel Perez, PhD, Michael Kleinberg, MD PhD, Rena G Lapidus, PhD, Aaron P. Rapoport, MD, Xiaoxuan Fan, PhD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-143160

Published: 2020

Journal Articles

Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

Justin N. Malinou, MD, Hanan Alkhaldi, MD, Saurabh Dahiya, MD, Olga Goloubeva, PhD MSc, Ali Bukhari, MD, Forat Lutfi, MD, Gabriela Sanchez-Petitto, MD, Santanu Samanta, MD, Aaron P. Rapoport, MD, Nancy M. Hardy, MD, Nicolette Minas, MS, Kathleen Ruehle, RN, Natalie Gahres, RN, Linda Ridge, RN, BA, CCTC, Pranshu Mohindra, MD, Jason Molitoris, MD, Jean A. Yared, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142140

Published: 2020

Journal Articles

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Ehren Dancy, MD, Alfred L. Garfall, MD, Adam D. Cohen, MD, Joseph A Fraietta, PhD, Megan Davis, PhD, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Edward A. Stadtmauer, MD FACP, Dan T. Vogl, MD, Adam Waxman, MD, Aaron P. Rapoport, MD, Michael C. Milone, MD PhD, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2018-99-115319

Published: 2018

Journal Articles

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

Blood (2018) 132 (Supplement 1): 91.

https://doi.org/10.1182/blood-2018-99-114152

Published: 2018

Journal Articles

Sublingual Microcirculatory Imaging As a Novel Tool to Monitor for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy

Andrew Deitchman, MD, Michael McCurdy, MD, Muhammad Gilani, MBBS, Aaron P. Rapoport, MD, Kathleen Ruehle, RN, Nancy M. Hardy, MD, Elizabeth Hutnick, RN, Jean Yared, MD, Saurabh Dahiya, MD

Blood (2018) 132 (Supplement 1): 5408.

https://doi.org/10.1182/blood-2018-99-115393

Published: 2018

Journal Articles

Impact of Body Mass Index (BMI) on Survival Endpoints in Multiple Myeloma

Mehmet Hakan Kocoglu, MD, Ameet Patel, MD, Aaron P. Rapoport, MD, Ning Ma, CRNP, Jennifer Ding, MD, Simran Elder, MD BA, Aneesha Hossain, MD, Ashraf Z. Badros, MD

Blood (2018) 132 (Supplement 1): 5750.

https://doi.org/10.1182/blood-2018-99-117915

Published: 2018

Journal Articles

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Cameron Dell, BS, Olga Goloubeva, PhD MSc, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Nancy M. Hardy, MD, Jean Yared, MD, Ning Ma, CRNP, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 2177.

https://doi.org/10.1182/blood.V130.Suppl_1.2177.2177

Published: 2017

Journal Articles

Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02 + Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286)

Aaron P. Rapoport, MD, Edward A Stadtmauer, MD, Karen Chagin, MD, Thomas Faitg, Malini Iyengar, Trupti Trivedi, Elliot Norry, MD, Tom Holdich, MD, Gwendolyn Binder-Scholl, PhD, Rafael Amado, MD, Frank Fang

Blood (2017) 130 (Supplement 1): 845.

https://doi.org/10.1182/blood.V130.Suppl_1.845.845

Published: 2017

Journal Articles

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Noa G. Holtzman, MD, Olga Goloubeva, PhD MSc, Zeba Singh, MBBS, Sameer Sawhney, MD, Ying Zou, MD PhD, Jean Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 3035.

https://doi.org/10.1182/blood.V130.Suppl_1.3035.3035

Published: 2017

Journal Articles

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Justin Kline, MD, Aaron P. Rapoport, MD, Adam M. Petrich, MD, Kenneth S. Cohen, MD, Sachdev P. Thomas, MD, Sreenivasa Nattam, MD, Krishna Rao, MD, Bethany Sleckman, MD, Walter Stadler, MD, Theodore Karrison, PhD, Sonali M. Smith, MD

Blood (2016) 128 (22): 4147.

https://doi.org/10.1182/blood.V128.22.4147.4147

Published: 2016

Journal Articles

Prospective Phase I Multi-Center Trial Incorporating Lenalidomide (LEN) into Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Patients with Double Hit (DHL) or Double Expressing (DEL) Lymphomas: Final Results

Chadi Nabhan, MD MBA, FACP, Theodore Karrison, PhD, Justin Kline, Kenneth Cohen, MD, Michael R. Bishop, MD, Reem Karmali, MD MS, Aaron P. Rapoport, MD, Parameswaran Venugopal, MD, James Wade, MD, Paul Fishkin, MD, Sonali M. Smith, MD

Blood (2016) 128 (22): 4191.

https://doi.org/10.1182/blood.V128.22.4191.4191

Published: 2016

Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z Badros, MD, Elizabeth Hyjek, MD PhD, Ning Ma, Alexander M. Lesokhin, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Ashlee Johnson, Cameron Dell, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2016) 128 (22): 490.

https://doi.org/10.1182/blood.V128.22.490.490

Published: 2016

Journal Articles

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z. Badros, MD, Mehmet H. Kocoglu, MD, Ning Ma, NP, Aaron P. Rapoport, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Cameron Dell, Nancy M. Hardy, MD, Jean Yared, MD, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2015) 126 (23): 506.

https://doi.org/10.1182/blood.V126.23.506.506

Published: 2015

Journal Articles

Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience

Ying S Zou, MD PhD, Yi Huang, PhD, Zhou Feng, Sin Chan, Shweta Shukla, Ina Lee, MDPhD, Zeba Singh, MD, Mehmet H. Kocoglu, MD, Aaron P. Rapoport, MD, Ning Ma, Nancy M. Hardy, MD, Jean Yared, MD, Maria R Baer, MD, Ashraf Z Badros, MD

Blood (2015) 126 (23): 1767.

https://doi.org/10.1182/blood.V126.23.1767.1767

Published: 2015

Journal Articles

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

Shahbaz A. Malik, MD, Saul Yanovich, MD, Aaron P. Rapoport, MD, Ashraf Z Badros, MD, Nancy M. Hardy, MD, Mehmet H. Kocoglu, MD, Alison Duffy, Kathleen Ruehle, Jennifer Nishioka, Olga Goloubeva, PhD, Jean Yared, MD

Blood (2015) 126 (23): 5507.

https://doi.org/10.1182/blood.V126.23.5507.5507

Published: 2015

Journal Articles

CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure

Ravi Vij, MD, Vera Hars, MS, William Blum, MD, Tsiporah B. Shore, Aaron P. Rapoport, MD, Thomas C. Shea, MD, Eva Hoke, Richard M. Stone, MD, Paula Friedman, Kouros Owzar, PhD, Steven M. Devine, MD

Blood (2014) 124 (21): 543.

https://doi.org/10.1182/blood.V124.21.543.543

Published: 2014

NARROW

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas

Pseudo-Allogeneic CAR-T Therapy after Allogeneic Stem Cell Transplantation in Relapsed/Refractory B-Cell NHL

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Detailed Immunophenotypic Profiling of Peripheral Blood Immune Cells in Patients with Hematologic Malignancies after Sars-Cov-2 Infection

Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

Sublingual Microcirculatory Imaging As a Novel Tool to Monitor for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy

Impact of Body Mass Index (BMI) on Survival Endpoints in Multiple Myeloma

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02 + Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286)

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Prospective Phase I Multi-Center Trial Incorporating Lenalidomide (LEN) into Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Patients with Double Hit (DHL) or Double Expressing (DEL) Lymphomas: Final Results

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only